Keros Therapeutics is not a profitable enterprise, which is a common financial profile for clinical-stage biotechnology and biopharmaceutical firms dedicated entirely to intensive research and development. Because the company does not yet market commercialized pharmaceutical products, it does not generate sustained product sales revenue. Instead, it incurs substantial ongoing operational expenses driven by multi-phase clinical trials, laboratory testing, and scientific salaries, resulting in net losses each fiscal year as it utilizes capital reserves to fund its pipeline advancement.